WELCOME
当前位置: 首页>>研发团队>>炎性疾病相关抗体>>正文
炎性疾病相关抗体

王佳佳

2019年10月18日         作者:         访问:[]

基本情况

王佳佳,博士,副教授,山西晋城人。

教育工作经历

2017.07-至今,河南大学,基础医学院,讲师

2016.05-2017.06,乔治亚州立大学,艺术与科学学院,博士后

2012.09-2015.12 南开大学,药学院,博士,导师:王鹏 教授

2009.09-2012.06 南开大学,药学院,硕士,导师:赵炜 教授

2005.09-2009.06 长治学院,化学系,学士

主要研究方向

微生物教研室,负责本科教学,讲授课程:《医学免疫学与病原微生物学》,《实验微生物学》;主要从事糖化学生物学相关研究。

承担项目

1.      国家自然科学基金青年项目,21907022,基于糖代谢调控的四价铂-氨基己糖配合物的设计、合成及其抗前列腺癌作用机制研究,2020/01-2022/1226万,主持;

2.      65批中国博士后科学基金面上资助,2019M652528Pt(IV)-FGN的设计、合成及抗肿瘤活性评价,2019/09-2021/98万,主持;

3.      河南省高等学校重点科研项目计划,20A350001,可调控糖代谢的铂类药物的开发,2020/01-2021/123万,主持;

4.      国家大学生创新性实验训练计划项目资助,201910475011,新型O-GlcNAc糖基化小分子探针的开发,2019/05-2021/52万,指导教师;

5.      河南省高等学校重点科研项目计划,19B1500034deo-GlcNAc及其类似物的抗菌活性和机制研究 2019/1-2020/12,主持;

6.      国家自然科学基金面上项目,21572105,糖肽疫苗的合成与免疫学评价,2016/01-2019/1277万元,在研,参加;

7.      国家自然科学基金面上项目,21572106,化学合成可被中和的抗凝血肝素寡糖,2016/1-2019/1276.8万,在研,参加;

8.      国家自然科学基金面上项目,21372130,糖基转移酶高通量鉴定方法的完善与应用,2014/01-2017/1285万元,已结题,参加;

9.      天津市应用基础与前沿技术研究,12JCYBJC18600O-GlcNAcase抑制剂对阿兹海默病Tau蛋白磷酸化的调控,2012/04-2015/310万元,已结题,参加;

10.   天津市重点支撑项目,化学多糖类药物-黄达肝癸钠五糖的大规模制备技术,13ZCZDSY0060050万,2013/04-2015/3,已结题,参加;

11.   天津市应用基础与前沿技术研究计划,15JCYBJC29000,胰岛素受体信号途径中糖基化蛋白的代谢标记及应用研究,2015/04-2018/03,已结题,参加;

近年研究成果

1.       Jing Li*#, Jiajia Wang#, Liuqing Wen, He Zhu, Shanshan Li, Kenneth Huang, Kuan Jiang, Xu Li, Cheng Ma, Jingyao Qu, Aishwarya Parameswaran, Jing Song, Wei Zhao, Peng George Wang*, An OGA-Resistant Probe Allows Specific Visualization and Accurate Identification of O GlcNAc-Modified Proteins in Cells. ACS. Chem. Biol. 2016, 11, 3002-3006 co-first author.

2.       Jiajia Wang, Yan Nie, Yunjuan Li, Yuanyuan Hou*, Wei Zhao, Jiagang Deng, Peng George Wang, Gang Bai, Identification of target proteins of mangiferin in mice with acute lung injury using functionalized magnetic microspheres based on click chemistry. J. Agric. Food. Chem. 2015, 63, 10013-10021.

3.       Jiajia Wang, Xiaomin Wang, Yunyan Zhao, Xiaoyao Ma, Yue Wan, Zhongwei Chen, Hao Chen, Hao Gan, Jing Li, Lei Li, Peng George Wang*, Wei Zhao*, Synthesis and biological evaluation of D-gluconhydroximo-1, 5-lactam and its oxime-substituted derivatives as pharmacological chaperons for the treatment of Gaucher disease. Med. Chem. Comm. 2016, 7, 365-370.

4.       Jiajia Wang, Harmon Greenway, Shanshan Li, Mohui Wei, Sameul J. Pollizi, Peng George Wang. Facile and stereo-selective synthesis of UDP-D-α-xylose and UDP-L-β-arabinose using UDP-sugar pyrophosphorylase. Front. Chem. 2018, 6, 163.

5.       Shanshan Li#, Jiajia Wang *#, Lanlan Zang#, Hailiang Zhu, Jianshuang Guo, Jiabin Zhang, Liuqing Wen, Yi Chen, Yanhong Li, Xi Chen, Peng George Wang* and Jing Li*. Production of Glycopeptide Derivatives for Exploring Substrate Specificity of Human OGA Toward Sugar Moiety. Front. Chem. 2018, 6, 646. co-first author

6.       Jiajia Wang #, Dongzhe Zhang #, Yinhang Wen, Xuefeng Cao, Jing Ma*, Peng George Wang*. Efficient chemoenzymatic synthesis of UDP-α-6-N3-glucose. Bioorg Med Chem Lett. 2019, 29, 1148-1151.co-first author

7.       Jiajia Wang, Yunyan Zhao, Wei Zhao, Peng Wang, Jing Li*, Total synthesis of N-butyl-1-deoxynojirimycin. J. CARBOHYD CHEM. 2016, 35(8-9): 445-454.

8.       Jing Ma, Hanfang Liu, Zhuoqing Xi, Jiuzhou Hou, Yingguang Li, Jie Niu, Tong Liu, Shuning Bi, Xin Wang, Chaojie Wang, Jiajia Wang*, Songqiang Xie* and Peng G. Wang. Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo. Front. Chem. 2018, 6, 386.

9.       Shanshan Li, Bingchen Yu, Jiajia Wang, Yueqin Zheng, Huajie Zhang, Margaret J. Walker, Zhengnan Yuan, He Zhu, Jun Zhang, Peng George Wang, Binghe Wang. Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response. ACS. Chem. Biol. 2018, 13(6):1686-1694.

10.    Shanshan Li, He Zhu, Jiajia Wang, Xiaomin Wang, Xu Li, Cheng Ma, Liuqing Wen, Bingchen Yu, Yuehua Wang, Jing Li* and Peng George Wang*, Comparative analysis of Cu (I)-catalyzed alkyne-azide cycloaddition (CuAAC) and strain-promoted alkyne-azide cycloaddition (SPAAC) in O-GlcNAc proteomics. Electrophoresis. 2016, 37, 1431–1436.

11.    Tiehai Li, Lina Guo, Yan Zhang, Jiajia Wang, Zhenxing Zhang, Jing Li, Wenpeng Zhang, Jianping Lin, Wei Zhao*, Peng George Wang*. Structure-activity relationships in a series of C2-substituted gluco-configured tetrahydroimidazopyridines as β-glucosidase inhibitors. Bioorgannic&Medicinal Chemistry, 2011, 19: 2136~2144.

12.    Tiehai Li, Lina Guo, Yan Zhang, Jiajia Wang, Zhonghua Li, Lin Lin, Zhenxing Zhang, Lei Li, Jianping Lin, Wei Zhao*, Jing Li*, Peng George Wang*. Design and synthesis of O-GlcNAcase inhibitors via ‘click chemistry’ and biological evaluations. Carbohydrate Research, 2011, 346,1083~1092.

13.    Tiehai Li, Hui Ye, Xuefeng Cao, Jiajia Wang, Yonghui Liu, Lifei Zhou, Qiang Liu, Wenjun Wang, Jie Shen*, Wei Zhao*, Peng Wang*. Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux. ChemMedChem, 2014, 9, 1071–1080.

14.    Tiehai Li, Zhonghua Li, Jing Li, Jiajia Wang, Lina Guo, Peng George Wang, Wei Zhao*. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold. Bioorganic & Medicinal Chemistry Letters, 2012, 22, 6854–6857.

上一条:卢锋
下一条:曹明亚

关闭